Top Markets
Coin of the day
BerGenBio ASA BerGenBio ASA

BerGenBio ASA

BGBIO
Rank in Stocks #37880
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage,... BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
Share Price
$0.051239
Last synced: 2025-11-24
Market Cap
$1.38M
Change (1 day)
-4.48%
Change (1 year)
-54.57%
Country
NO
Trade BerGenBio ASA (BGBIO)

Category

Dividend yield history for BerGenBio ASA (BGBIO)
BerGenBio ASA (stock symbol: BGBIO) dividend yield (TTM) as of 2026: 0
Average dividend yield, last 5 years : 0.00%
Dividend yield history for BerGenBio ASA (BGBIO) from 2026 to 2026
Dividend Yield at the end of each year (TTM)
Year Dividend Yield Change
Not enough data for the provided dates.
Dividend yields (TTM) for similar companies or competitors